Abstract β 2 -Glycoprotein I (β 2 GPI) is a 50 kDa molecule proposed as a principal target of 'autoimmune' antiphospholipid antibodies (aPL). We have used deleted mutants (DM) representing different domains of β 2 GPI (I-IV, IV-V and V) for immunization of naive mice and studied the characteristics of the respective murine IgG preparations in comparison with affinity-purified IgG from two patients with primary antiphospholipid syndrome. Immunization with β 2 GPI and with the DM produced anti-β 2 GPI antibodies, part of which reacted with negatively charged phospholipids (PL), whereas reactivity with cardiolipin was evident only in the IgG from mice immunized with β 2 GPI. These results are consistent with the presumption that aPL are induced following the in vivo association of β 2 GPI (used for immunization) with resident negatively charged PL. Accordingly, DM which either lack the PL binding site or aPL attachment locus did not elicit, upon immunization, antibodies reactive with PL. Further, murine anti-β 2 GPI IgG and human 'autoimmune' aPL were similar, albeit not identical, in terms of DM requirement for PL binding and charge dependency. Murine antibodies and human aPL, regardless of their binding characteristics, were found to bind significantly to platelets upon their activation with thrombin and to promote platelet activation. The results of the current study emphasize the dissimilarities between human 'autoimmune' aPL and murine anti-β 2 GPI. Thus, anti-β 2 GPI antibodies to different DM as well as human aPL are capable of binding and activating human platelets provided β 2 GPI is present.
Introduction β 2 -Glycoprotein I (β 2 GPI) is a 50 kDa protein cofactor required It has been suggested that 'autoimmune' aPL are directed against a cryptic epitope exposed on the structure of β 2 GPI, for the binding of 'autoimmune' antiphospholipid antibodies (aPL) to negatively charged phospholipids (PL) (1) (2) (3) . This following its association with negatively charged synthetic surfaces (4) or PL (5). Alternatively, β 2 GPI may support the protein is a member of the complement control protein family containing five (I-V) short consensus repeats ('sushi binding of aPL from 'autoimmune' sera due to its increased density, facilitated by the interaction with PL (6). domains'). In recent years, intensive work has been carried out to elucidate the nature of the interaction between PL, Autoimmune aPL are heterogeneous in terms of binding properties and while some react directly with β 2 GPI, others β 2 GPI and aPL, with the aim of gaining insight into the pathogenesis of the prothrombotic state in the antiphosphocross-react with negatively charged PL (7,8). There is no consensus on the clinical significance of specific subsets of lipid syndrome (APS). aPL and anti-β 2 GPI antibodies with regard to their association with the manifestations of APS, probably reflecting a multifactorial etiopathogenesis of this yet incompletely understood syndrome.
Recently, it has become apparent that the fifth domain of β 2 GPI is responsible for the attachment to PL (9,10); however, controversy still exists regarding the location of epitope(s) which provide the cofactor activity for the binding of 'autoimmune' aPL to β 2 GPI or alternatively to the complex formed following its association with PL (1, 11) .
In an attempt to resolve some of these enigmas, human The recent construction of deleted mutants (DM) of β 2 GPI conjugated anti-rabbit IgG combined with enhanced chemiexpressed by a baculovirus system (16-17) has prompted luminescence were used. Lanes 1-2, 50 ng of affinity-purified human us to explore the immune reaction following immunization of anti-β 2 GPI antibodies; lanes 3-4, 50 ng of affinity-purified mouse antimice with these proteins. Herein we provide a description of β 2 GPI antibodies. Lanes 5-9, purified human β 2 GPI (at concentrations of: 100, 20, 4, 2 and 1 ng respectively).
the binding characteristics of antibodies to three of these DM in comparison with affinity-purified antibodies from two patients with the primary APS. Furthermore, the binding properties of these antibodies are complemented by a study Affinity purification of human aPL of their binding and activating properties in a human platelet system in the absence and with addition of β 2 GPI.
Affinity purification of human aPL was performed as previously described (18) with slight modifications. First, 5 ml of human sera was mixed with 2.5 ml of phosphatidylserine micelles in Methods 0.15 M NaCl (3 mg/ml) and the mixture was incubated at 37°C for 1 h and 4°C overnight with constant mixing. The Antigens mixture was then centrifuged at 30,000 g for 15 min and the supernatant was removed. The washing procedure was Recombinant DM representing different domains of β 2 GPI repeated twice. After the third wash, the pellet was resus-(DM I-IV, IV-V and V) were used for mouse immunization pended in 1 ml of 1 M NaI and incubated for 1 h with gentle (17). Human β 2 GPI was purified from the serum of a healthy mixing. Then, 0.5 ml of chloroform was added, and the mixture adult as previously described (12) . mixed for 1 min and allowed to stand. The mixture was Mice separated into two layers and the top aqueous layer containing anti-phosphatidylserine antibodies was recovered and Female BALB/c mice (6-8 weeks old) were purchased from dialyzed against PBS overnight. The dialyzed extract conthe Sackler Faculty of Medicine, Tel-Aviv University, Israel.
taining antibodies was purified further using Protein GSepharose chromatography. Absence of contamination with Patients β 2 GPI of human antibodies was confirmed using the method Two patients with primary APS were selected for the comparatdescribed in Fig. 1 . ive studies. Both patients were diagnosed by the occurrence of thromboembolic events, recurrent fetal losses and high Anti-phospholipid ELISA titers of IgG aPL, part of which were reactive with β 2 GPI.
A modified ELISA to determine reactivity of the mouse and human antibodies to PL was performed as previously Immunization protocol described (17). Briefly, microtiter plates (Nunc, Maxisorp, Mice were actively immunized in their hind footpads with 10 Denmark) were coated either with an anionic PL [cardiolipin µg of the following DM: whole molecule (WM), I-IV, V, IV-V, (CL), phosphatidylserine (PS) and phosphatidylinositol (PI)] emulsified in complete Freund's adjuvant. Three weeks later, and phosphatidylcholine (PC), all from Sigma (St Louis, MO), a booster immunization was given at the same area, with 10 at a concentration of 50 µg/ml dissolved in ethanol, except µg of the respective preparation dissolved in PBS. The mice for PC (choloroform:methanol, 1: 3). Plates were dried under were bled from their retro-orbital plexuses at monthly intervals.
vacuum and blocked with TBS containing 0.5% gelatin. The plates were then washed three times with TBS and different Purification of mouse IgG concentrations of mouse or human IgG preparations were added to the wells treated with human β 2 GPI (5 µg/ml for 30 IgG from pooled mouse sera from all study groups was purified by Protein G-Sepharose column (Pharmacia, min) or 0.1% gelatin/TBS alone. The binding of the antibodies was detected with goat anti-mouse or anti-human IgG alkaline Uppsala, Sweden). Absence of contamination of the IgG preparation with β 2 GPI was confirmed by immunoblot with phosphatase conjugate and the addition of substrate (pnitrophenylphosphate). The results were expressed as mouse anti-β 2 GPI antibodies using enhanced chemiluminescence; demonstrated in Fig. 1 .
absorbance at 405 nm (OD 405 ).
Anti-β 2 GPI ELISA Preparation of platelet suspension for FACS Venous blood was drawn from healthy donors, who had not Aliquots of 1 µg/ml β 2 GPI or different DM were incubated used any medication for the previous 10 days, into 15% ACD overnight in 50 mM bicarbonate buffer, pH 9.6, at 4°C in 96-(0.73% citric acid, 2.2% sodium citrate, 2.45% dextrose, pH well polystyrene plates (Nunc). After three washings with TBS, 4.5). Platelet-rich plasma (PRP) was prepared by centrifuging blocking was performed with 0.5% gelatin/TBS for 2 h (as for the blood at 180 g for 15 min. Prostaglandin E 1 (PGE 1 , 100 the anti-PL ELISA). The plates were then washed three times ng/ml) was added to the PRP to inhibit platelet release and and human or murine IgG (diluted in 0.1% gelatin/TBS) was aggregation during subsequent procedures. PRP was then then added and incubated for 2 h at room temperature. After centrifuged at 1200 g for 10 min. The resulting platelet pellet three washings, alkaline phosphatase conjugated goat antiwas resuspended in Tyrode's buffer (137 mM NaCl, 2.8 mM human IgG or anti-mouse IgG respectively diluted in 0.1% KCl, 0.4 mM NaH 2 PO 4 .2H 2 O, 12 mM NaHCO 3 , 5 mM glucose, gelatin/TBS (1:10,000) was added for 2 h. After an additional 0.35% BSA and 5 mM EDTA, pH 6.5). Platelets were washed three washings, the substrate p-nitrophenylphosphate in a twice in the same buffer in the presence of PGE 1 . Finally they sodium carbonate buffer (pH 9.8) was added and absorbance were resuspended in Tyrode's buffer without PGE 1 and EDTA was read at 405 nm.
(pH 7.4) to which 1 mM calcium chloride was added.
Effect of DM in the modified anti-CL ELISA FACS analysis for assessment of binding and activation of human platelets with mouse and human IgG CL (50 µg/ml in ethanol) was coated on plain polystyrene 96-well plates (Nunc) and allowed to evaporate at 4°C overnight.
Washed platelets were diluted with Tyrode's buffer (pH 7.4) After three washings with TBS, the wells were blocked with to 2.5ϫ10 7 /ml. Then, 40 µl of the platelet suspension was 0.5% gelatin/TBS for 2 h at room temperature. The plates incubated for 10 min with or without 5 µl of β 2 GPI (80 µg/ml), were washed and different DM (WM, I-IV, V or I-III) were 5 µl of α-thrombin (0.05 U/ml) and 5 µl of anti-P-selectin IgG added at different concentrations (2.5-15 µg/ml) for 30 min conjugated to phycoerythrin. Then, 5 µl of mouse IgG (80 µg/ at room temperature. Following the addition of the IgG, bound ml) β 2 GPI or 5 µl of IgG from two APS patients was added antibodies were detected using 1:10,000 dilution of goat antiand the incubation was continued for 30 min. Platelets were human or anti-mouse IgG conjugated to alkaline phosphatase washed twice and resuspended in 90 µl of Tyrode's buffer. (Sigma) and the addition of its substrate p-nitrophenylphosThen, 10 µl of goat anti-mouse IgG or goat anti-human IgG phate. Color was read in an ELISA reader (SLT Laboratory conjugated to FITC was added and incubation was repeated Instruments, Vienna, Austria) at 405 nm.
for 30 min. Subsequently, platelets were washed and resuspended in 0.6 ml of 1% formaldehyde in Tyrode's buffer for Immunoblot assays and detection of murine IgG reactivity FACS analysis. The stained antibodies were used at saturating with different DM conditions and isotype-matched antibodies were used as a non-specific control. From each sample, 5000 platelets were Different DM (WM, I-IV, I-III, II-V, II-IV, III-V and V; 2 µg/ analyzed using an EPICS-XL Coulter flow cytometer. The lane) were subjected to SDS-PAGE using 12% acrylamide results were expressed as mean fluorescence intensity separating gel. The separated proteins were transferred onto obtained in three or four independent experiments. nitrocellulose sheets by a constant current of 2.5 mA/cm 3 for 1 h. The sheets were then incubated with TBS, pH 7.4, Results containing 1% bovine serum albumin (Sigma). After three washings with TBS/0.05% Tween 20 and 1% BSA. Individual
Binding of mouse and human IgG to β 2 GPI and PL sheets were incubated with mouse IgG (aWM, aI-IV and aV).
The purified IgG preparations obtained from mice immunized Following further washings, the sheets were incubated with with the different recombinant preparations of β 2 GPI and from peroxidase-conjugated goat anti-mouse IgG (Jackson patients with primary APS reacted both with PL and with Immuno Research, USA) and developed with 4 chloro-1-β 2 GPI coated on the plates. As shown in Fig. 2(A Fifty percent of the maximal activity of affinity-purified human 2B). IgG to DM I-IV and V displayed negligible binding to aPL was determined as follows: modified anti-CL ELISA (in negatively charged PL and to neutral PL (OD Ϯ SD, n ϭ 5; the presence of β 2 GPI) was performed as described, using 0.054 Ϯ 0.002 and 0.064 Ϯ 0.003 respectively), whereas several concentrations of human antibodies. After subtraction reactivity with β 2 GPI was clearly evident (mean OD Ϯ SD, of the background binding, the concentration of IgG that n ϭ 5; 1.116 Ϯ 0.106). Affinity-purified aPL from the patients gave half of the maximal OD (405 nm) represented 50% with primary APS reacted with both negatively charged PL maximum binding. Affinity-purified human aPL diluted to 50% (mean OD Ϯ SD, n ϭ 5; 0.599 Ϯ 0.010) and β 2 GPI (mean the maximum binding (2 µg/ml) were mixed with varying OD Ϯ SD, n ϭ 5, 0.565 Ϯ 0.022) (data not shown). concentrations (100-0 µg/ml) of IgG from mice immunized Effect of different DM on the binding of mouse aWM and with DM and non-immunized controls. The mixtures were human aPL to PL added to ELISA plates coated with CL and treated with β 2 GPI, and the remaining activity of human antibodies was measured
The addition of native β 2 GPI enhanced the binding of mouse aWM IgG (Fig. 3A) and human aPL (Fig. 3B) to CL. Addition as described previously. To determine modified ELISA (described in Methods) was employed to detect cofactor requirements for binding of murine anti-β 2 GPI and affinityreactivity of mouse IgG to coated negatively charged CL (A) and purified human aPL to CL, different concentration of DM (WM, I-IV, neutral PC (B) (5 µ/ml). Murine IgG to β 2 GPI (WM) and to DM (I-IV, V and I-III) were added to CL-coated plates (50 µg/ml in ethanol). IV-V and V) displayed clear reactivity to CL in the presence β 2 GPI, Bound murine IgG (WM, I-IV and V) (A) or affinity-purified human whereas 'pure' anti-CL reactivity (in the absence of β 2 GPI) was IgG (B) were detected using a 1:10,000 dilution of goat anti-mouse evident only in IgG obtained by immunization with WM. Reactivity or anti-human IgG (respectively) conjugated to alkaline phosphatase with neutrally charged PL was only detected in the latter IgG (WM).
and addition of its substrate p-nitrophenylphosphate.
of both DM I-IV and I-III had an inhibitory effect on the binding of mouse aWM IgG to CL-coated plates, whereas no ELISA. The assay was employed also in 0.15 M NaCl buffer to effect on the binding of human aPL to PL was noted. DM V eliminate the binding of charge-dependent mouse and human had no effect on the binding of mouse aWM to CL, yet antibodies with no significant competition (data not shown). inhibited the binding of human aPL in the respective assay.
Effect of ionic strength on antibody binding Binding of mouse antibodies to DM by ELISA and immunoblot
The charge dependencies of mouse IgG preparations and By employing ELISA, it was observed that binding of aWM human aPL from the patient with primary APS were determined (Fig. 4A ) was significant to all DM (which represent all the by using buffers with different ionic strength in the solid-phase domains within β 2 GPI). The aI-IV (Fig. 4B) and aV (Fig. 4C) assays ( Fig. 6A and B) . The binding capacities of mouse and bound the domains which correspond to the preparation used human antibodies were tested in modified anti-CL ELISA and for immunization. By immunoblotting, the binding of aWM anti-β 2 GPI ELISA. The binding of mouse aWM, as well as the (Fig. 5A) is clear to nearly all DM (and WM). A similar binding binding of aI-IV and aV to β 2 GPI-coated plates was not affected pattern was evident regarding the aI-IV (Fig. 5B) pendent experiments, one of which is presented in Fig. 7 . Slightly increased binding to platelets of mouse IgG to the Effect of thrombin and β 2 GPI on binding of murine anti-β 2 GPI different DM was evident as compared with IgG from a normal IgG to human platelets and P-selectin expression mouse (Fig. 7A) . The binding of mouse IgG was followed by a moderate increase of P-selectin expression, suggesting activaThe binding of mouse antibodies and control mouse IgG to resting and thrombin-preactivated platelets was assessed by tion of the platelets. Following platelet activation with thrombin P-selectin-phycoerythrin IgG was added to all tubes. After washing, were used to assess the effect of ionic strength on the binding of anti-mouse IgG-FITC was added. Platelets were incubated again, murine IgG and affinity-purified IgG from a representative patient washed, fixed with 1% formaldehyde and subjected to FACS. with APS. The binding of the IgG was assayed employing the anti-β 2 GPI (A) and modified anti-CL ELISA (B).
(with no addition of β 2 GPI), pronounced binding of anti-β 2 GPI IgG was evident (Fig. 7B) . Herein, thrombin induced extensive P-selectin expression by platelets treated with either normal IgG or IgG from the immunized mice. β 2 GPI (with no addition of thrombin) led to a moderate increase in binding and Pselectin expression of mouse antibodies (to DM and WM), yet platelets as compared with control mouse IgG. No differences were noted with regard to the intensity of platelet binding between the different mouse IgG (to DM or to WM).
Binding of human aPL IgG to platelets and P-selectin 0.28 in patient 2 as compared with 1.33 Ϯ 0.27 in the normal expression volunteer, P Ͻ 0.001). At the same time, P-selectin expression on normal platelets was significantly increased only by the As shown in Fig. 8 , in the presence of thrombin and β 2 GPI, IgG of the first patient (2.29 Ϯ 0.38 in patient 1; 1.69 Ϯ increased binding to platelets of human aPL derived from 0.19 in patient 2 as compared with 1.36 Ϯ 0.17 in the two patients was evident by FACS and expressed as mean fluorescence intensity (4.89 Ϯ 0.62 in the patient 1; 3.43 Ϯ control sample).
Discussion
obtain competition between mouse and human antibodies imply that antibodies induced following immunization of mice The purpose of the present study was to characterize the with human β 2 GPI are not identical to human 'autoimmune' polyclonal immune response to different preparations of β 2 GPI aPL, despite several similar characteristics. in solid-phase and in vitro human platelet assays with special
The role of aPL in the pathogenesis of APS has received reference to human 'autoimmune' aPL. We presumed that the considerable attention in recent years, as manifested by the study of the polyclonal response to the different DM, despite establishment of several animal models (15, (19) (20) (21) . In a very its heterogeneous nature (as compared with mAb), could recent study (22) , the authors have shown that antibodies represent more convincingly the diverse spectrum of autoantielicited following immunization of mice with β 2 GPI possess bodies in the sera of patients with APS. We have confirmed thrombogenic properties, evident in a 'pinch-injury' murine the presence of two populations of antibodies in response to model. These results reinforce previous data suggesting that immunization with the complete structure of β 2 GPI, i.e. 'pure' immunization of naive mice with human β 2 GPI results in anti-β 2 GPI antibodies and antibodies cross-reactive with a clinical picture resembling human APS, manifested by negatively charged PL (Fig. 2A) . However, IgG obtained thrombocytopenia, increased fetal loss and prolonged activfollowing immunization with DM I-IV and V was not crossated thromboplastin time (15). reactive with CL, implying that the complete structure of β 2 GPI Special emphasis has been put on platelets as possible (which unlike the DM studied, contains both the PL binding targets of 'pathogenic' aPL, considering both the occurrence site and cofactor activity) is required for the production of of thrombocytopenia and a prothrombotic state in APS (23-aPL. This observation is consistent with the presumption that 26). Platelet assays bear several advantages relevant to the cross-reactive aPL are produced in response to the complex current study. (i) In vitro assays could be performed in the formed following attachment of β 2 GPI to PL in vivo (or in absence and the presence of β 2 GPI, thus dissecting its role adjuvant), binding which resides in the fifth domain of β 2 GPI.
in the binding and activation of platelets by aPL.
(ii) Platelets Furthermore, the buffer experiments (Fig. 6 ) have shown that are prototypic cells which (upon activation) display loss of the murine IgG population to the different DM possessed membrane asymmetry, with partial 'scrambling' of lipids, the significant charge dependency of binding in a modified antiresult of which is the exposure on the outer surface of the CL-ELISA, whereas binding to β 2 GPI-coated plates was of negatively charged PL concomitant with the internalization of higher avidity. Human aPL displayed moderate charge the positively charged phosphatidylenthanoleamine (27) . The dependency both in the modified anti-CL and anti-β 2 GPI exposure of PS upon platelet activation has been suggested ELISA, suggesting that some of the β 2 GPI reactivity may not to provide a negatively charged surface, thus promoting aPL be specific (Fig. 6) .
binding in a β 2 GPI-dependent manner (28). This system Several authors have suggested that the immune response seemed appropriate for the current study by providing an induced following immunization of rabbits (14) and mice (12- established in vitro assay that could be correlated with the 13,15) with human β 2 GPI resembles the autoantibody pattern solid-phase studies and furnish a fair additional tool for the in humans with APS. We have thus chosen representative comparison of human and murine aPL. patients with primary APS and applied similar assays to study Despite the previously described dissimilarities in the solidthe characteristics of their given antibodies and compared phase assays, platelet studies have shown that human and them with the immune response towards the DM. Indeed, the all murine IgG preparations possessed binding and activating pattern of antibodies found in the patients resembled mostly properties. In the washed platelet system (where β 2 GPI is that found in the mice immunized with the complete structure depleted from the medium), the binding and platelet activation of β 2 GPI. However, competition assays between murine antipotential of mouse antibodies was nearly negligible and could β 2 GPI antibodies and affinity-purified human aPL did not either be attributed to minor activation of the manipulated reveal similar binding specificities, probably reflecting either platelets or to the basal binding of the antibodies to neutral PL the heterogeneous nature of antibodies found in the sera of (Fig. 2B ). However, with the addition of β 2 GPI, enhancement of patients with APS or the differences in the binding characterplatelet binding and activation (by mouse antibodies and istics of mouse and human antibodies. An additional differhuman aPL) occurred manifested by P-selectin expression ence between human 'autoimmune' aPL and mouse aWM upon their surface. The β 2 GPI-dependent increased binding was found with regard to their binding to the different DM.
and activation of platelets was marked when mouse IgG (to Hence, β 2 GPI expectedly enhanced the binding of both DM and to WM) was assayed and not with control IgG, thus murine (aWM) and human (aPL) antibodies to PL. DM I-IV supporting a pronounced interaction of the antibodies with and I-III did not display similar enhancement in humans, human platelets. It is of interest that aV and aI-IV IgG, which probably due to the lack of a PL binding site residing in the could be taken to represent two 'opposing', non-overlapping fifth domain. The inhibition of binding of mouse anti-β 2 GPI populations (as can be observed by the lack of spreading of antibodies to PL could be explained by the capture of the autoimmune response evident in the ELISA and immunoblot latter IgG by the unbound DM I-IV (lacking the V domain) as assays) were both capable of binding and activating human was also evident by the ELISA and immunoblot assays (Figs platelets with similar intensity (Fig. 7) . Platelet activation 4 and 5). This binding prevented the detection of mouse induced by thrombin resulted in increased binding of all antibodies which remained complexed in the fluid phase.
mouse IgG (including control) to platelets (Fig. 7B) . The Supporting this presumption is the similar inhibition obtained integrative explanation of the functional assays is that the using DM I-III. mouse antibodies specific for the native structure of β 2 GPI or to DM (displaying high affinity) bound β 2 GPI complexed with The solid-phase studies complemented by the inability to
